|
Synonyms: compound 1086 [WO2017175066] | compound 32 [PMID: 41054342] | MKP-10241 | MKP10241
Compound class:
Synthetic organic
Comment: Deziglipel is the INN for a G-protein-coupled receptor 119 (GPR119) agonist, as presented in WHO INN Proposed List 135 (July 2026). It is proposed for the treatment of steatohepatitis and type 2 diabetes in this INN record. It is one of the compounds claimed in patents held by Mankind Pharma that are disigned to target the GPR119/incretin axis as a mechanism to treat metabolic disorders [1]. and deziglipel is a structural match for the declared GPR119 clinical lead MKP10241 [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| Activates GRP119 by 87% in a cAMP assay [1]. |
| Selectivity at GPCRs | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||